Compare Neurocrine Biosciences Inc (NBIX) vs Northrop Grumman Corporation (NOC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Northrop Grumman Corporation — how do they compare? Neurocrine Biosciences Inc trades at $142.44 (market cap $14.36B), while Northrop Grumman Corporation trades at $480.72 (market cap $68.83B). The key difference: Northrop Grumman Corporation is far larger — about 4.8× Neurocrine Biosciences Inc's market cap, and Northrop Grumman Corporation pays a 2.04% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Neurocrine Biosciences Inc for 23 Days and Northrop Grumman Corporation for 81 Days on average.
| NBIX | NOC | |
|---|---|---|
Market Cap | $14.36B | $68.83B |
Volume | 1,237,180 | 1,081,989 |
Sector | Health | Industrials |
52-Week High | $185.50 | $768.02 |
52-Week Low | $123.10 | $473.46 |
Typical Hold Time | 23 Days | 81 Days |
Enterprise Value | $14.37B | $82.81B |
Dividend Yield | — | 2.04% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $141.25, down 1.55% on the day, with a bearish technical signal driven by moving averages. Fundamentally, the company shows strong profitability with a 20.91% net income margin and has beaten EPS estimates in recent quarters. Recent news highlights pipeline progress in Prader-Willi syndrome and executive appointments.
The outlook is supported by robust analyst consensus (86.49% buy ratings) and a $204.18 price target, but risks include execution of pipeline diversification and potential pricing pressure on key drug Ingrezza. The stock offers growth potential from expanding rare-disease assets, contingent on successful commercialization.
Northrop Grumman (NOC) trades at $484.48, up 2.33% on the day, but technical indicators signal a bearish trend. The company demonstrates strong fundamentals with consistent earnings beats, a net income margin of 10.48%, and a robust backlog. Recent news highlights a competitive setback with Boeing winning a major Navy contract, though the company maintains solid defense sector positioning.
The outlook is mixed; strong profitability and analyst buy ratings support upside to a $600.62 consensus target, but near-term technical pressure and contract loss risks pose challenges. Revenue growth and dividend stability offer investor appeal, though sector volatility and execution risks require monitoring.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Northrop Grumman Corporation
Northrop Grumman is a defense contractor that is diversified across short-cycle and long-cycle businesses. The firm's segments include aeronautics, mission systems, defense services, and space systems. The company's aerospace segment creates the fuselage for the massive F-35 program and produces various piloted and autonomous flight systems. Mission systems creates a variety of sensors and processors for defense hardware. The defense systems segment is a long-range missile manufacturer. Finally, the company's space systems segment produces various space structures, sensors, and satellites.
Read more on NOC →
